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Obstructive sleep apnea–hypopnea syndrome (OSAHS) is frequently present in patients 
with severe obesity, but its prevalence especially in women is not well defined. OSAHS and 
non-alcoholic fatty liver disease are common conditions, frequently associated in patients 
with central obesity and metabolic syndrome and are both the result of the accumulation 
of ectopic fat mass. Identifying predictors of risk of OSAHS may be useful to select the 
subjects requiring instrumental sleep evaluation. In this cross-sectional study, we have 
investigated the potential role of hepatic left lobe volume (HLLV) in predicting the pres-
ence of OSAHS. OSAHS was quantified by the apnea/hypopnea index (AHI) and oxygen 
desaturation index in a cardiorespiratory inpatient sleep study of 97 obese women [age: 
47 ± 11 years body mass index (BMI): 50 ± 8 kg/m2]. OSAHS was diagnosed when AHI 
was ≥5. HLLV, subcutaneous and intra-abdominal fat were measured by ultrasound. After 
adjustment for age and BMI, both HLLV and neck circumference (NC) were independent 
predictors of AHI. OSAHS was found in 72% of patients; HLLV ≥ 370 cm3 was a predictor 
of OSAHS with a sensitivity of 66%, a specificity of 70%, a positive and negative predictive 
values of 85 and 44%, respectively (AUC = 0.67, p < 0.005). A multivariate logistic model 
was used including age, BMI, NC, and HLLV (the only independent predictors of AHI in 
a multiple linear regression analyses), and a cut off value for the predicted probability of 
OSAHS equal to 0.7 provided the best diagnostic results (AUC = 0.79, p < 0.005) in 
terms of sensitivity (76%), specificity (89%), negative and positive predictive values (59 
and 95%, respectively). All patients with severe OSAHS were identified by this prediction 
model. In conclusion, HLLV, an established index of visceral adiposity, represents an 
anthropometric parameter closely associated with OSAHS in severely obese women.
Keywords: non-alcoholic fatty liver disease, obstructive sleep apnea–hypopnea syndrome, hepatic left volume, 
metabolic syndrome, insulin resistance, morbid obesity
Abbreviations: AHI, apnea/hypopnea index; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotrans-
ferase; AT, abdominal thickness; ATP-III, adult treatment panel; AUC, area under the curve; BMI, body mass index; CT, computed 
tomography; γ-GT, γ-glutamyltransferase; HDL, high-density lipoprotein; HLLV, hepatic left lobe volume; HOMA, homeostatic 
model assessment—insulin resistance; IAF, intra-abdominal fat; IDF, International Diabetes Federation; IQR, interquartile range; 
LDL, low-density lipoprotein; MS, metabolic syndrome; NAFLD, non-alcoholic fatty liver disease; NC, neck circumference; NPV, 
negative predictive value; ODI, oxygen desaturation index; OGTT, oral glucose tolerance test; OSAHS, obstructive sleep apnea–
hypopnea syndrome; PPV, positive predictive value; R, Pearson correlation coefficient; Rho, Spearman correlation coefficient; 
ROC, receiver operating characteristic curve; SCF, subcutaneous fat; SpO2, nocturnal O2 saturation; TG, triglycerides.
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inTrODUcTiOn
Obstructive sleep apnea–hypopnea syndrome (OSAHS), an 
emerging public health issue, is characterized by recurrent 
episodes of upper airway occlusion during sleep, which results 
in reduction or cessation of the airflow, and lead to chronic inter-
mittent hypoxia and sleep fragmentation (1). The pathogenetic 
factors of OSAHS are manifold and yet not completely under-
stood. The main cause seems to be an anatomical upper airway 
narrowing, where the increased negative intrathoracic pressure 
during inspiration exceeds the counteracting forces of the dilat-
ing muscles (2–4). The cyclical recurrence of obstructions and 
arousals may cause instability of central respiratory motor output, 
thus contributing to the genesis of apneic episodes (5).
Obstructive sleep apnea–hypopnea syndrome affects a sig-
nificant proportion of the adult population, mainly males, and its 
prevalence increases with increasing body mass index (BMI) and 
advancing age (1, 6, 7). Currently, in the United States, among 
adults, approximately 13% of men and 6% of women have moder-
ate-to-severe OSAHS [apnea/hypopnea index (AHI) ≥ 15] while 
14% of men and 5% of women have an AHI ≥ 5 together with 
symptoms of daytime sleepiness (1, 8). The mechanisms linking 
obesity to OSAHS include pharyngeal narrowing due to fatty 
tissue in the lateral airway walls, muscle functional impairment 
due to fatty deposits, enlargement of the abdomen resulting in 
reduced lung volumes, decreased longitudinal tracheal traction 
forces and increased tendency of pharyngeal collapse during 
inspiration, the low-grade systemic inflammation associated with 
obesity (3, 9).
On the basis of animal models (10), it has been postulated 
that leptin resistance developed by obese patients may impair the 
neuroanatomic interaction necessary for stable breathing, thereby 
contributing to the genesis of OSAHS (11). The disruption of 
normal sleep and chronic intermittent hypoxia starts a vicious 
circle by worsening obesity and may explain the close associa-
tion between OSAHS and some of the features of the metabolic 
syndrome (MS), including hypertension, insulin resistance, 
and type 2 diabetes, ultimately leading to cardiovascular and 
cerebro-vascular illness (12–15). The name “syndrome Z” has 
been proposed for the association between MS and OSAHS (16) 
and the inclusion of this sleep and breathing disorder among the 
manifestations of MS has been also suggested (17).
The Cardiometabolic Think Tank convened on June 20, 
2014 in Washington, DC, has tried to categorize subtypes and 
stages of MS in order to find an optimal care model for patients 
at increased cardiometabolic risk. The subtype with the excess 
visceral adipose tissue as main pathophysiologic mechanism is 
characterized by the presence of sleep disordered breathing and 
non-alcoholic fatty liver disease (NAFLD) (18).
Patients with MS frequently have an increased fat (triglycer-
ide) accumulation in the liver, called NAFLD, and hepatic insulin 
resistance. With the increasing worldwide prevalence of obesity, 
NAFLD has become the most common cause of abnormal liver 
function in the general adult population (19–23). Studies con-
ducted in humans and mice have suggested that OSAHS could be 
a detrimental factor potentially responsible for the exacerbation 
of liver injury in obesity (3).
The diagnosis of NAFLD is usually established by ultrasound 
and can be confirmed by liver biopsy (24).
We have shown that the ultrasound measurement of the 
hepatic left lobe volume (HLLV) correlated with the total volume 
of liver measured with MR and is an excellent indicator of visceral 
adiposity clustering with parameters defining MS (25, 26).
Little is known about the prevalence of OSAHS and the impact 
of this medical disorder on metabolic risk factors in morbidly 
obese patients; especially in women in whom it frequently 
remains underdiagnosed (27).
The aim of this cross-sectional study was to evaluate in a group 
of morbidly obese women with symptoms and signs associated 
with OSAHS the prevalence of OSAHS and the relationships 
between the severity of OSAHS and several anthropometric 
measurements with particular interest to HLLV.
MaTerials anD MeThODs
This is a retrospective study that included 97 morbidly obese 
women (BMI >  35  kg/m2) referred to our Obesity Center for 
evaluation of obesity and its comorbidities and had, therefore, 
been submitted to cardio-respiratory sleep study for the clinical 
suspicion of OSAHS (excessive daytime sleepiness, choking or 
gasping during sleep, recurrent awakenings from sleep, impaired 
concentration). All patients signed a written consent for the 
treatment of their clinical data for purpose of research. The study 
did not require additional testing beside the protocol for evalua-
tion of patients candidate to bariatric surgery. Exclusion criteria 
for this study were: history of hypothalamic–pituitary diseases, 
hypercortisolism, goiter, self-reported daily alcohol consump-
tion >  20  g, current or past use of illicit drugs or hepatotoxic 
medications, viral hepatitis as assessed by conventional serum 
markers, a previous diagnosis of a disease potentially causing 
liver enlargement (e.g., storage diseases, autoimmune hepatitis), 
pregnancy or breast feeding within the 12-month period before 
enrollment. A careful endocrinological evaluation was also per-
formed to reveal undiagnosed dysfunctions that required specific 
therapy and to evaluate the presence of hormonal abnormalities 
associated with OSAHS. 33 subjects were taking hypoglycemic 
agents, 7 hypolipidemic agents, and 4 hypouricemic agents.
anthropometric, clinical, and laboratory 
Measures
Clinical, hematological, and instrumental examinations were 
performed according to the Italian guidelines for obesity (28). 
Anthropometric measures were determined in the morning after 
an overnight fast. Body weight was measured using a stand-on-
scale in a hospital gown to the nearest 1/10th of a kilogram (SECA 
gmbh & co. —Germany) and height was measured to the nearest 
centimeter using a wall-mounted stadiometer (Health o meter.
inc., Bridgeview, IL, USA). Neck circumference (NC) was deter-
mined at the level of the cricothyroid membrane. Blood pressure 
on admission was recorded with a large cuff while the patient 
was recumbent. Venous blood was obtained after an overnight 
fasting for measurement of glucose, triglycerides (TG), high-
density lipoprotein (HDL), low-density lipoprotein (LDL) and 
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total cholesterol, uric acid, aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), γ-glutamyltransferase (γ-GT), 
and alkaline phosphatase (ALP). The homeostasis model of insu-
lin resistance (HOMA) was calculated based on fasting serum 
glucose and insulin concentrations (29). In 64 patients who 
were not taking hypoglycemic agents, an oral glucose tolerance 
test was performed in the morning with measurement of serum 
insulin and glucose when fasting, and every 30 min for 3 h after 
the ingestion of the glucose load (75 g).
hllV and abdominal Fat Measurements
Ultrasound examination for measurement of HLLV, subcutane-
ous fat (SCF) and intra-abdominal fat (IAF) was performed, 
as previously described (25, 26). Briefly, the ellipsoid formula 
(width ×  height ×  length ×  0.52) was employed to calculate the 
HLLV. Thickness of the SCF was taken 1 cm over the transversal 
umbilical vein, by measuring the distance between the skin and the 
external face of the muscular fascia, while IAF thickness was defined 
as the distance between the internal face of the same muscle and the 
anterior wall of the aorta. Abdominal thickness (AT) was defined 
as the distance between the skin and the anterior wall of the aorta.
sleep apnea assessment
An inpatient cardiorespiratory overnight sleep study was per-
formed by means of a polygraph (Somno Check; Vivisol). To 
consider a study valid, a minimum sleep duration of 5  h was 
required. Parameters measured included oronasal flow by nasal 
cannula, thoraco-abdominal movements, pulsoxymetry, snor-
ing, and body position. The results recorded by the instrument 
were scored by the attending physician expert in sleep studies 
who was maintained blinded to the characteristics of the patient. 
Nocturnal O2 saturation (SpO2) was recorded during the entire 
length of the night. Apnea was defined by the absence of airflow 
for > 10 s while hypopnea was defined as any airflow reduction 
of >50% that lasted for >10  s and resulted in oxyhemoglobin 
desaturation (3% dip rate). AHI was defined as the sum of the 
numbers of apnea and hypopneas per hour of sleep and OSAHS 
was diagnosed when AHI was ≥ 5. Oxygen desaturation index 
(ODI) was defined as the number of desaturations per hour of 
sleep and OSAHS was diagnosed when ODI was ≥5.
According to the American Sleep Disorders Association Task 
Force criteria (30), sleep-related obstructive breathing events 
were scored as mild when between 5 and 15 events/h of sleep, as 
moderate when between 15 and 30, and as severe when they were 
>30 events/h of sleep. Patients with a negative cardiorespiratory 
sleep study showing diurnal sleepiness underwent a complete 
polysomnography to avoid false-negative diagnosis in accord-
ance with the American Sleep Disorders Association report (31).
statistical analysis
The sample size calculation was based on the number of patients 
needed to demonstrate an association between HLLV and AHI. 
A target sample size of 84 patients provided a power of 0.80 with 
an alpha of 0.05 to detect a modest correlation equal to 0.30. With 
97 patients recruited in this study, the statistical power was equal 
to 0.85. Descriptive statistics were calculated for the cohort as a 
whole and then separately by OSAHS diagnosis. Statistical tests 
used to compare groups included Student’s t test and ANOVA for 
difference in mean values, Mann–Whitney U and Kruskal–Wallis 
tests for skewed variables, Pearson Chi-square test for difference 
in counts and frequency. The Levene’s test was used to assess the 
equality of variances between OSAHS groups. The Kolmogorov–
Smirnov test was used to assess normality of data; logarithmic 
transformations were applied to skewed variables (AHI, insulin 
concentrations and HOMA index) to approximate a Gaussian dis-
tribution. Pearson (R) and Spearman (Rho) correlation coefficients 
were employed to quantify associations for Gaussian and skewed 
variables, respectively. Multiple linear regression analyses using the 
forward selection algorithm were carried out to identify the most 
significant anthropometric predictors of AHI, SpO2, and ODI.
The receiver operating characteristic (ROC) curve was 
calculated to identify the cutoff value of both HLLV and NC, 
which better discriminated between subjects with and without 
OSAHS in terms of highest combined sensitivity and specificity 
(i.e., highest Youden index). The positive group included subjects 
with OSAHS (AHI ≥ 5) while the negative group those without 
OSAHS (AHI < 5). Sensitivity was defined as the percentage of 
subjects having OSAHS who were correctly classified as having 
this disease, while specificity was the percentage of subjects 
without OSAHS who were correctly classified as not having this 
disease.
A multivariate logistic analysis including all the determinants 
of OSAHS as determined through univariate analysis was carried 
out to calculate the predicted probability of OSAHS diagnosis 
(AHI ≥ 5) based on the logistic formula: 1/[1 + exp(−SCORE)], 
where SCORE was the linear combination of logistic model coef-
ficients multiplied for the values of the respective determinant of 
OSAHS. A ROC curve analysis was then performed to determine 
the best cutoff value of the predicted probability of OSAHS diag-
nosis according to the highest Youden index, as above.
A p-value < 0.05 was considered statistically significant. Data 
are presented as a mean ± SD or median with inter-quartile range 
(IQR), as indicated. Statistical analyses were performed in SPPS 
(version 25; Armonk, NY, USA: IBM Corp.Armonk, NY, USA: 
IBM Corp.).
resUlTs
Average age of the study cohort (±SD) was 47 ± 11 years (range: 
24–67) and BMI was 50 ± 8 kg/m2 (range: 36–81). The physical, 
hematological, and clinical characteristics are reported in Table 1. 
OSAHS was found in 70 patients (median AHI = 14, IQR: 8–25). 
Of all subjects with OSAHS, 53% had a mild OSAHS, 26% mod-
erate OSAHS, and 21% severe OSAHS. Average SpO2 was lower 
in patients with OSAHS compared to those without (p < 0.005). 
Median ODI was higher in patients with OSAHS compared to 
those without (p < 0.001). On average, patients with OSAHS were 
8-year older (p < 0.005) and had greater IAF and HLLV compared 
to patients without OSAHS (both p < 0.05) despite similar body 
weight, BMI, and SCF. In addition, higher levels of γ-GT were 
observed in patients with OSAHS (p < 0.05), and there was a posi-
tive association between AHI and γ-GT (Rho = 0.21; p < 0.05). 
No significant associations were observed between AHI and ALT 
(p = 0.21), AST (p = 0.22) or ALP (p = 0.49). Out of 70 patients with 
Table 1 | Demographic and anthropometric (A), clinical (B) and laboratory characteristics (C) of the study population.
all subjects (N = 97) Without obstructive sleep apnea–hypopnea 
syndrome (Osahs) (N = 27)
With Osahs (N = 70)
a
Age (years) 46.6 ± 10.7 40.8 ± 9.5 48.8 ± 10.3*
Body weight (kg) 126.9 ± 20.9 125.1 ± 16.8 127.6 ± 22.3
Body mass index (kg/m2) 49.6 ± 7.5 48.5 ± 6.0 50.0 ± 8.1
NC (cm) 38.4 ± 3.2 37.5 ± 2.7 38.7 ± 3.3
Subcutaneous fat (mm) 41.6 ± 14.2 41.6 ± 12.9 41.6 ± 14.8
Intra-abdominal fat (mm) 101.1 ± 32.6 90.3 ± 20.0 105.7 ± 35.8*
Abdominal thickness (mm) 142.1 ± 34.6 130.0 ± 21.1 147.3 ± 37.9*
Hepatic left lobe volume (cm3) 448.0 ± 242.7 344.6 ± 144.5 487.9 ± 261.3*
b
Metabolic syndrome (%)
ATP III criteria 62.9% 48.1% 68.6%
IDF criteria 64.9% 48.1% 71.4%*
Apnea/hypopnea index (AHI) (events/h) 18.5 ± 25.4 2.5 ± 1.6 24.6 ± 27.6*
Median [interquartile range (IQR)] 8.3 (4.7–18.4) 2.2 (1–4) 14 (8–25)*
AHI < 5 (no OSAHS) 27 (28%) 27 (100%) 0 (0%)
AHI ≥ 5 and <15 (mild) 37 (38%) 0 (0%) 37 (53%)
AHI 15–30 (moderate) 18 (19%) 0 (0%) 18 (26%)
AHI > 30 (severe) 15 (15%) 0 (0%) 15 (21%)
Mean nocturnal O2 saturation 92.7 ± 4.5 94.6 ± 2.9 92.0 ± 4.7*
Total sleep time (h) 8 ± 0.7 8.2 ± 0.7 8 ± 0.6
Oxygen desaturation index (events/h) 20.9 ± 24.1 7.0 ± 8.9 26.5 ± 26*
Median (IQR) 13.0 (5.4–23.0) 3.8 (1.3–7.8) 16 (10.2–29.6)*
c
Fasting glucose (mg/dL)a 108.3 ± 45.3 102.2 ± 30.8 111.2 ± 51.0
2-h glucose (mg/dL)a 150.4 ± 74.9 145.2 ± 78.1 153.0 ± 74.2
Fasting insulin (μU/mL)a 13.3 ± 14.0 11.9 ± 11.2 13.9 ± 15.2
Median (IQR) 9 (6–14.5) 7 (5–13) 10 (6–16)
2-h insulin (μU/mL)a 73.0 ± 57.5 64.5 ± 48.2 77.4 ± 62.0
Median (IQR) 63 (34–88) 62 (32–88) 69 (41–89)
Insulin peak (μU/mL)a 98.3 ± 67.2 87.5 ± 71.2 103.9 ± 65.2
Median (IQR) 83 (59–113) 72 (45–107) 91 (64–116)
HOMA indexa 3.7 ± 4.7 3.5 ± 4.9 3.9 ± 4.6
Median (IQR) 2.2 (1.4–3.7) 1.6 (1.3–2.8) 2.3 (1.6–3.9)*
Total cholesterol (mg/dL)b 195.5 ± 34.3 192.8 ± 40.1 196.6 ± 31.9
High-density lipoprotein (mg/dL)b 50.7 ± 15.9 51.4 ± 14.3 50.4 ± 16.7
Low-density lipoprotein (mg/dL)b 123.3 ± 29.9 116.3 ± 31.1 126.3 ± 29.2
Triglycerides (mg/dL)b 150.9 ± 67.8 146.1 ± 61.6 152.8 ± 70.5
Uric acid (mg/dL)c 5.6 ± 1.2 5.4 ± 1.1 5.7 ± 1.3
Aspartate aminotransferase (U/L) 23.8 ± 12.9 22.1 ± 13.4 24.4 ± 12.7
Alanine aminotransferase (U/L) 29.8 ± 16.8 27.0 ± 14.1 30.9 ± 17.8*
γ-glutamyltransferase (U/L) 35.8 ± 39.6 27.4 ± 23.4 39.0 ± 44.1*
Alkaline phosphatase (U/L) 125.7 ± 73.4 116.0 ± 74.8 129.4 ± 73.1
Data are reported as mean ± SD, or frequency (%). For skewed variables, median values with IQR are also reported.
*p < 0.05 vs. without OSAHS.
a64 patients not taking hypoglycemic agents.
b90 patients not taking hypolipidemic agents.
c93 patients not taking hypouricemic agents.
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OSAHS, 48 (69%) and 50 (71%, p < 0.05) patients were classified 
as with the MS according to ATP-III and IDF criteria, respectively.
anthropometric Determinants of ahi  
and spO2
Apnea/hypopnea index (Rho  =  0.36, p  <  0.005) and SpO2 
(R = −0.30, p = 0.003) correlated with HLLV in a positive and 
negative fashion, respectively (Figures  1A,C). Similar associa-
tions with AHI (Rho = 0.24, p < 0.05) and SpO2 (Rho = −0.21, 
p < 0.05) were observed for NC (Figures 1B,D). ODI correlated 
with HLLV (Rho = 0.36, p < 0.001) and with NC (Rho = 0.27, 
p = 0.009) in a positive fashion (Figures 1E,F). Accordingly, both 
HLLV and NC increased with severity of OSAHS (trend p < 0.05, 
Figure  2). Further, IAF (AHI: Rho =  0.33, p <  0.005; SpO2: 
Rho = −0.36, p < 0.005) and AT (AHI: Rho = 0.37, p < 0.005; 
SpO2: Rho = −0.35, p <  0.005) were associated with AHI and 
SpO2 while there was no correlation with SCF (AHI: Rho = 0.08, 
p = 0.43; SpO2: Rho = −0.01, p = 0.99). In separate multivari-
ate models each including age and BMI, HLLV (p < 0.005) and 
FigUre 1 | Correlations between anthropometric variables and respiratory paramenters in the cohort of 97 obese women. Relationships between the hepatic left 
lobe volume (HLLV) and the apnea/hypopnea index (AHI) (a) the mean percent oxygen saturation [SpO2, (c)] and the oxygen desaturation index (ODI) (e). 
Relationship between neck circumference and AHI (b) mean percent oxygen saturation [SpO2, (D)] and (ODI), (F). AHI and ODI values are reported on a logarithmic 
scale, i.e., LOG10(1 + AHI) and LOG10(1 + ODI) which can handle zero values. R: Pearson’s correlation coefficient (*p < 0.05).
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NC (p < 0.05), but not IAF (p = 0.47), AT (p = 0.48) nor SCF 
(p = 0.84), were associated with AHI.
In a full model including age, BMI, HLLV and NC, both HLLV 
(partial R2 = 9%, p = 0.001) and NC (partial R2 = 7%, p = 0.004) 
were independent predictors of AHI, such that a 100-cm3 increase 
in HLLV and 1-cm increase in NC were independently associated 
with mean increases in AHI of 15 and 9%, respectively (Table 2).
In a full model including age, BMI, HLLV, and NC, HLLV 
(partial R2 =  9%, p =  0.005) was an independent predictor of 
ODI, such that a 100-cm3 increase in HLLV was independently 
associated with an average 13% increase in ODI (Table 2).
To further illustrate the independent effects of HLLV and NC 
on AHI, we categorized subjects in four subgroups according to 
the median values of HLLV and NC (Figure 3) and women with 
FigUre 3 | Cumulative effects of hepatic left lobe volume (HLLV) and neck 
circumference (NC) on the apnea/hypopnea index (AHI). Subjects were 
categorized in four subgroups according to the median values of HLLV 
(=408 cm3) and NC (=38 cm) in the whole cohort. The variances of AHI 
values were not significantly different among the four subgroups by the 
Levene’s test (p = 0.07). *p < 0.05 by ANOVA.
Table 2 | Most significant anthropometric predictors of AHI, SpO2, and ODI 
according to multiple linear regression analyses.
Predictors ahi (log. values) spO2 (%) ODi (log. values)
Age (years) 0.010 (0.004) −0.123 (0.037) 0.007 (0.004)
p = 0.012* p = 0.002* p = 0.073
BMI (kg/m2) 0.012 (0.006) −0.161 (0.056) 0.015 (0.006)
p = 0.043* p = 0.005* p = 0.013*
NC (cm) 0.039 (0.013) −0.321 (0.126) 0.033 (0.014)
p = 0.004* p = 0.012* p = 0.019*
HLLV (100 cm3) 0.060 (0.018) −0.347 (0.17) 0.052 (0.018)
p = 0.001* p = 0.044* p = 0.005*
Intercept −1.775 (0.561) 120.312 (5.405) −1.473 (0.578)
Explained variance R2 = 0.310* R2 = 0.297* R2 = 0.282*
Beta coefficients in each cell are reported as mean values with SE and significance 
(*p < 0.05).
Beta coefficient of VLES is expressed by increase of 100 cm3 of VLES.
Prior to regression analysis, AHI and ODI values were expressed in a logarithmic scale, 
e.g., LOG10(1 + AHI)/LOG10(1 + ODI), to approximate a Gaussian distribution.
AHI, apnea/hypopnea index; BMI, body mass index; HLLV, hepatic left liver volume; 
NC, neck circumference; SpO2, mean nocturnal O2 saturation; ODI, oxygen 
desaturation index.
FigUre 2 | Hepatic left lobe volume (HLLV) (a) and neck circumference (b) average values for each class of obstructive sleep apnea–hypopnea syndrome 
(OSAHS). OSAHS severity is defined as mild for apnea/hypopnea index (AHI) ≥ 5 and < 15; moderate for AHI ≥ 15 and ≤ 30; and severe for AHI > 30. Error bars 
represent the 95% confidence interval of the mean. The variances of HLLV (p = 0.08) and neck circumference (p = 0.38) were not significantly different among 
OSAHS categories by the Levene’s test. *: p < 0.05 for linear trend by ANOVA.
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a HLLV > 408 cm3 and NC > 38 (n = 14, median AHI = 15) had 
higher AHI compared to those with an HLLV <  408  cm3 and 
NC < 38 cm (n = 25, median AHI = 5, p < 0.005). Similarly, NC 
(partial R2 = 5%, p < 0.05) and HLLV (partial R2 = 3%, p < 0.05) 
were independent predictors of SpO2 after adjustment for age and 
BMI (Table 2).
Predictors of Osahs Diagnosis
In the whole cohort of 97 women, HLLV was a parameter 
significantly associated with OSAHS by ROC curve analysis 
(AUC = 0.67, 95% CI: 0.57–0.76, p < 0.005) (Figure 4A). A cutoff 
value of 370 cm3 had a sensitivity of 66% (95% CI: 53–77%), a 
specificity of 70% (95% CI: 50–86%), and positive and negative 
predictive values (NPVs) of 85 and 44%, respectively, in identify-
ing subjects with OSAHS. Conversely, NC did not discriminate 
between subjects with or without OSAHS (AUC = 0.59, p = 0.19) 
(Figure 4B). Considering the full logistic model, HLLV (p < 0.05, 
OR = 1.003, 95% CI: 1.001–1.006), but not NC, (p = 0.09) was 
the only independent predictor of OSAHS diagnosis after 
adjustment for age (p < 0.005) and BMI (p = 0.86) in the multi-
variate analysis. According to the results of the logistic analysis, 
a predicted probability of OSAHS (AHI ≥ 5) was calculated on 
the basis of age, BMI, NC, and HLLV applying the following 
formula: 1/[1 + exp(−SCORE)], where SCORE = −9.806 + age 
(years) × 0.075 + BMI (kg/m2) × 0.007 + NC (cm) × 0.155 + HLLV 
Table 3 | Comparison between the predicted probability of obstructive sleep 
apnea–hypopnea syndrome (OSAHS) (calculated by multivariate logistic model 
which includes age, BMI, HLLV, NC) and the actual prevalence of OSAHS.
Predicted 
probability  
of Osahs
no Osahs  
[apnea/hypopnea 
index (ahi) < 5]
Mild Osahs 
(ahi ≥ 5  
and <15)
Moderate 
Osahs  
(ahi: 15–30)
severe 
Osahs 
(ahi > 30)
<0.70 N = 24 (89%) N = 13 (35%) N = 4 (22%) N = 0 (0%)
≥0.70 N = 3 (11%) N = 24 (65%) N = 14 (78%) N = 15 (100%)
FigUre 4 | Receiver operating characteristic (ROC) curves for the diagnostic performance of hepatic left lobe volume (HLLV) (a) and neck circumference (NC) (b) to 
identify obstructive sleep apnea syndrome (OSAHS) in the cohort of 97 obese patients. Thin lines show 95% confidence intervals; arrows point at the optimal cutoff 
as defined by the Younden index for diagnostic sensitivity and specificity. AUC, area under the curve. *p < 0.05 by ROC curve analysis.
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(cm3) × 0.003. The predicted probability of OSAHS achieved the 
highest performance in the classification of OSAHS (AUC = 0.79, 
95% CI: 0.70–0.87, p < 0.005) and a cut-off value equal to 0.70 
yielded to the best diagnostic results in terms of combined 
sensitivity (76%), specificity (89%), NPV (59%), positive pre-
dictive value (95%), and accuracy (79%). Among subjects with 
a predicted probability of OSAHS ≥  0.70, only 3 (5%) did not 
actually present OSAHS (false positive patients) while among the 
subjects with a predicted probability of OSAHS < 70%, 17 (41%) 
presented OSAHS (false negative patients). Results for each class 
of OSAHS severity are reported in Table 3. Of note, all patients 
with severe OSAHS were identified by this prediction model.
DiscUssiOn
Obstructive sleep apnea–hypopnea syndrome and NAFLD are 
very common in patients with central obesity and MS (18). 
Regional fat distribution is different in each sex, with fat tending 
to accumulate primarily around the waist in men and around the 
hips in women; the predominance of central obesity in men partly 
explains the difference in the prevalence of OSAHS between the 
sexes. In the Wisconsin Sleep Study Cohort, women had a higher 
BMI than men at each level of respiratory disturbance index and 
less severe apnea at an equivalent degree of obesity (8, 32). Male 
patients with OSAHS have a greater amount of visceral adipose 
tissue by computed tomography as compared to BMI-matched 
men without sleep-disordered breathing, and visceral but not 
subcutaneous fat appears significantly correlated with indices of 
sleep apnea (33).
Age is another risk factor for OSAHS especially in women (8), 
probably due to the protective effect of female sex hormones before 
menopause. Bixler et al. in a epidemiologic study of OSAHS in 
women found that the prevalence was higher in postmenopausal 
women that in premenopausal women (3.9 vs 0.6%) (34).
Female subjects are referred less frequently to sleep clinics 
probably also because of gender-related symptom differences; 
women with OSAHS may refer atypical symptoms such as fatigue, 
headaches, mood disorders (32, 35).
In studies conducted in numerically limited populations with 
predominance of male subjects affected by overweight or mild 
and moderate obesity, higher values of BMI, waist circumference 
(or waist–hip ratio), neck circumference were almost always 
associated with the presence and severity of OSAHS (9, 36–39). 
However, anthropometric parameters appear inadequate in 
predicting the risk of OSAHS and the systematic use of polysom-
nography is recommended (40, 41). Waist circumference may not 
be reliable in severe obesity due to its imprecision and inability to 
palpate the iliac crest besides the confounding effect of cutaneous 
plications; in addition, it cannot distinguish between subcutane-
ous and intra-abdominal fat (IAF). In severe obesity, it was also 
found a weak association between AHI and excessive daytime 
sleepiness or other symptoms and signs of OSAHS especially in 
females. Obesity itself is a cause of poor subjective assessment of 
sleep quality and sleepiness (15, 42, 43).
Recognizing the risk factors and predictors of OSAHS may 
be of particular relevance in women. Indeed, women are more 
frequently addressed to bariatric surgery than men and patients 
with OSAHS are particularly vulnerable during anesthesia 
and sedation, and display an increased risk of developing res-
piratory and cardiopulmonary postoperative complications (44). 
Identifying anthropometric, clinical, and laboratory predictors of 
risk of OSAHS would be useful in clinical practice in order to 
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avoid expensive investigations such as polysomnography and to 
select patients that should be submitted to specific diagnostic test.
Few studies have analyzed the prevalence of OSAHS in mor-
bidly obese women; the most important risk factors identified 
were BMI, age, and menopausal status (42, 43, 45).
In our sample, OSAHS was found to be present in 72% of 
obese women with a BMI greater than 35. Approximately half 
of the patients had mild OSAHS, one quarter had moderate 
OSAHS and one quarter of patients manifested a severe form 
of obstructive sleep apnea. Patients with OSAHS were older and 
had a greater visceral fat estimated by ultrasound compared to 
patients without OSAHS, despite similar body weight, BMI, NC, 
and SCF. γ-GT, but not transaminase, levels positively correlated 
with OSAHS quantified by AHI index, suggesting that OSAHS 
could be an independent risk factor for NAFLD. Lack of associa-
tion between AHI index and serum transaminases may depend 
on the limited statistical power of our study sample. However, 
liver enzymes alone are not sensitive enough to characterize 
NAFLD. In this regard, it should be noted that non-invasive liver 
biomarkers-based scores have been developed to evaluate the 
extent of liver injury, which are independently associated with 
the severity of nocturnal hypoxia (46, 47).
As expected, neck circumference (NC) and IAF (measured by 
ultrasound) correlated with AHI and ODI and with the severity of 
OSAHS. We also observed a positive relationship between HLLV 
and AHI. ODI correlated with HLLV in a positive fashion as well. 
Interestingly, HLLV showed a stricter correlation with parameters 
describing OSAHS than NC.
According to the ROC curve analysis, only HLLV but not 
NC did discriminate between subjects with or without OSAHS. 
Similarly, according to the logistic regression, when dichotomiz-
ing a continuous variable (AHI) in two groups, the statistic 
contribution of NC was lost.
These results confirm the role of liver enlargement as a marker 
of visceral adiposity, which may facilitate the identification of 
individuals who are at increased risk of OSAHS in addition to 
the other known risk factors of OSAHS such as age, BMI, and 
NC. Indeed, prediction logistic model, including age, BMI, NC, 
and HLLV, displayed a discriminative ability (evidenced by AUC 
value of 0.79). However, the NPV was too low (59%) to propose 
this model in a clinical setting. While it is useful to reduce the 
number of false positives to avoid unnecessary instrumental sleep 
studies, a relevant number of false negative results may lead to 
a failure to treat OSAHS with potential adverse consequences. 
Nevertheless, among the false negative, there were no patients 
with severe OSAHS (AHI > 30) indicating that the model can 
identify all patients affected by OSAHS requiring urgent and 
active treatment.
At present, we cannot establish whether OSHAS and NAFLD 
can influence each other in terms of occurrence and progression 
or if they are merely unrelated expressions of ectopic fat deposi-
tion. Future studies including HLLV and other non-invasive 
scores (46, 47) may be helpful in this regard.
In conclusion, the results of this study indicate that in 
severe obese women HLLV is a powerful and better anthro-
pometric predictor of OSAHS than neck circumference, and 
we have identified a prediction logistic model based only on 
four parameters (age, BMI, NC, and HHLV), which is capable 
of predicting all severe forms of OSAHS requiring active 
treatment.
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